NovoRapid

NovoRapid

insulin aspart

Manufacturer:

Novo Nordisk

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Insulin aspart
Indications/Uses
DM in adult, adolescents & childn ≥2 yr.
Dosage/Direction for Use
Adult & childn Individualised dosage: Usually between 0.5 & 1 U/kg/day. Normally used in combination w/ intermediate or long-acting insulins given at least once daily.
Administration
May be taken with or without food: SC: Administer immediately before or soon after a meal. May be administered IV under medical supervision. May be used for Continuous SC Insulin Infusion (CSII) in pump systems.
Contraindications
Special Precautions
Travelling between different time zones may require change in timing of dosing & meals. Inadequate dosing or discontinuation of treatment may lead to hyperglycemia & diabetic ketoacidosis. Avoid omission of a meal or unplanned strenuous physical exercise. Patients w/ delayed absorption due to concomitant diseases or medication. Concomitant illness especially infections & feverish conditions. Concomitant diseases of kidney, liver or affecting the adrenal, pituitary or thyroid gland diseases. Careful in switching to another type or brand of insulin. Continuous rotation of inj site w/in a given area to reduce inj site reactions. Dose adjustment in case of insulin antibodies. May affect ability to drive or operate machinery in case of hypoglycaemia.
Adverse Reactions
Hypoglycemia, urticaria, rash, eruptions, refraction disorders, diabetic retinopathy, lipodystrophy, inj site reactions, oedema, peripheral neuropathy, anaphylactic reactions.
Drug Interactions
May develop heart failure w/ thiazolidinediones. May reduce insulin requirement w/ oral hypoglycaemic agents, MAOIs, β-blockers, ACE inhibitors, salicylates, anabolic steroids & sulphonamides. May increase insulin requirements w/ OC, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone & danazol. May mask symptoms of hypoglycaemia w/ β-blockers. May intensify or reduce hypoglycaemic effect w/ alcohol. May increase/decrease insulin requirements w/ octreotide & lanreotide.
ATC Classification
A10AB05 - insulin aspart ; Belongs to the class of fast-acting insulins and analogues. Used in the treatment of diabetes.
Presentation/Packing
Form
NovoRapid FlexPen 100 u/mL
Packing/Price
3 mL x 5 × 1's
Form
NovoRapid penfill 100 u/mL
Packing/Price
3 mL x 5 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in